急性冠状动脉综合征中的糖尿病与抗血小板治疗 - Suppr

Suppr

超能文献

Diabetes and antiplatelet therapy in acute coronary syndrome.

作者信息

Ferreiro José Luis, Angiolillo Dominick J

机构信息

University of Florida College of Medicine-Jacksonville, 655 W 8th St., Jacksonville, FL 32209, USA.

出版信息

Circulation. 2011 Feb 22;123(7):798-813. doi: 10.1161/CIRCULATIONAHA.109.913376.

DOI:10.1161/CIRCULATIONAHA.109.913376

PMID:21343595

Abstract

摘要

相似文献

Diabetes and antiplatelet therapy in acute coronary syndrome.

Circulation. 2011 Feb 22;123(7):798-813. doi: 10.1161/CIRCULATIONAHA.109.913376.

Emerging insights on antiplatelet therapy. Introduction.

Am J Cardiol. 2009 Feb 2;103(3 Suppl):1A-3A. doi: 10.1016/j.amjcard.2008.11.015.

[Evaluation of platelet response to antiplatelet drugs. An important clue for cardiologists and cardiosurgeons].

Kardiol Pol. 2007 Oct;65(10):1266-9.

Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus.

Expert Rev Cardiovasc Ther. 2011 Jun;9(6):697-710. doi: 10.1586/erc.11.76.

Novel antiplatelet therapy.

Am Heart J. 2010 Oct;160(4):595-604. doi: 10.1016/j.ahj.2010.06.007.

Recent therapeutic approaches to platelet activation in coronary artery disease.

Pharmacol Ther. 2010 Aug;127(2):108-20. doi: 10.1016/j.pharmthera.2010.05.001. Epub 2010 May 28.

New directions in antiplatelet therapy.

Circ Cardiovasc Interv. 2012 Jun;5(3):433-45. doi: 10.1161/CIRCINTERVENTIONS.111.966176.

Platelet monitoring for PCI: which test is the one to choose?

Hamostaseologie. 2009 Nov;29(4):376-80.

[Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].

Ter Arkh. 2009;81(1):84-7.

Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?

Cardiol Clin. 2008 Nov;26(4):629-37. doi: 10.1016/j.ccl.2008.07.003.

引用本文的文献

Integrated metabolic-inflammatory risk assessment: HbA1c/HDL-c and hsCRP-to-albumin ratios synergistically predict major adverse cardiovascular events in post-PCI STEMI patients.

Lipids Health Dis. 2025 Sep 13;24(1):280. doi: 10.1186/s12944-025-02707-2.

One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme.

EuroIntervention. 2025 Jun 16;21(12):e668-e680. doi: 10.4244/EIJ-D-24-00897.

Dual antiplatelets therapy prescription trends and mortality outcomes among senior citizens with acute coronary syndrome: insights from the Malaysian National Cardiovascular Disease Database.

J Geriatr Cardiol. 2025 Feb 28;22(2):237-245. doi: 10.26599/1671-5411.2025.02.004.

Real-time platelet P2Y receptor occupancy as a promising pharmacodynamics biomarker for bridging the gap between PK/PD of clopidogrel therapy.

Acta Pharm Sin B. 2025 Jan;15(1):484-493. doi: 10.1016/j.apsb.2024.08.008. Epub 2024 Aug 13.

Comparison of 1-Year Clinical Outcomes Between Ticagrelor Versus Clopidogrel in Type 2 Diabetes Patients After Implantation of Small Diameter Stents.

Anatol J Cardiol. 2025 Jan 7;29(2):95-103. doi: 10.14744/AnatolJCardiol.2024.4603.

Clopidogrel-Mediated P2Y Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD.

JACC Basic Transl Sci. 2024 Mar 25;9(7):865-876. doi: 10.1016/j.jacbts.2024.03.003. eCollection 2024 Jul.

Acute Hyperglycemia-Induced Injury in Myocardial Infarction.

Int J Mol Sci. 2024 Aug 4;25(15):8504. doi: 10.3390/ijms25158504.

Tailoring Antithrombotic Regimens for Percutaneous Coronary Intervention Patients with High Bleeding and Ischemic Risk (): Individualized Management and Genotype-Guided De-escalation.

Rev Cardiovasc Med. 2023 Dec 12;24(12):348. doi: 10.31083/j.rcm2412348. eCollection 2023 Dec.

Depression Following Acute Coronary Syndrome: A Review.

Rev Cardiovasc Med. 2023 Sep 5;24(9):247. doi: 10.31083/j.rcm2409247. eCollection 2023 Sep.

Methionine sulfoxide reductase B2 protects against cardiac complications in diabetes mellitus.

Diabetol Metab Syndr. 2024 Jul 5;16(1):149. doi: 10.1186/s13098-024-01390-0.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Diabetes and antiplatelet therapy in acute coronary syndrome.

作者信息

Ferreiro José Luis, Angiolillo Dominick J

机构信息

University of Florida College of Medicine-Jacksonville, 655 W 8th St., Jacksonville, FL 32209, USA.

出版信息

Circulation. 2011 Feb 22;123(7):798-813. doi: 10.1161/CIRCULATIONAHA.109.913376.

DOI:10.1161/CIRCULATIONAHA.109.913376

PMID:21343595

Abstract

摘要

相似文献

Diabetes and antiplatelet therapy in acute coronary syndrome.

Circulation. 2011 Feb 22;123(7):798-813. doi: 10.1161/CIRCULATIONAHA.109.913376.

Emerging insights on antiplatelet therapy. Introduction.

Am J Cardiol. 2009 Feb 2;103(3 Suppl):1A-3A. doi: 10.1016/j.amjcard.2008.11.015.

[Evaluation of platelet response to antiplatelet drugs. An important clue for cardiologists and cardiosurgeons].

Kardiol Pol. 2007 Oct;65(10):1266-9.

Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus.

Expert Rev Cardiovasc Ther. 2011 Jun;9(6):697-710. doi: 10.1586/erc.11.76.

Novel antiplatelet therapy.

Am Heart J. 2010 Oct;160(4):595-604. doi: 10.1016/j.ahj.2010.06.007.

Recent therapeutic approaches to platelet activation in coronary artery disease.

Pharmacol Ther. 2010 Aug;127(2):108-20. doi: 10.1016/j.pharmthera.2010.05.001. Epub 2010 May 28.

New directions in antiplatelet therapy.

Circ Cardiovasc Interv. 2012 Jun;5(3):433-45. doi: 10.1161/CIRCINTERVENTIONS.111.966176.

Platelet monitoring for PCI: which test is the one to choose?

Hamostaseologie. 2009 Nov;29(4):376-80.

[Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].

Ter Arkh. 2009;81(1):84-7.

Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?

Cardiol Clin. 2008 Nov;26(4):629-37. doi: 10.1016/j.ccl.2008.07.003.

引用本文的文献

Integrated metabolic-inflammatory risk assessment: HbA1c/HDL-c and hsCRP-to-albumin ratios synergistically predict major adverse cardiovascular events in post-PCI STEMI patients.

Lipids Health Dis. 2025 Sep 13;24(1):280. doi: 10.1186/s12944-025-02707-2.

One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme.

EuroIntervention. 2025 Jun 16;21(12):e668-e680. doi: 10.4244/EIJ-D-24-00897.

Dual antiplatelets therapy prescription trends and mortality outcomes among senior citizens with acute coronary syndrome: insights from the Malaysian National Cardiovascular Disease Database.

J Geriatr Cardiol. 2025 Feb 28;22(2):237-245. doi: 10.26599/1671-5411.2025.02.004.

Real-time platelet P2Y receptor occupancy as a promising pharmacodynamics biomarker for bridging the gap between PK/PD of clopidogrel therapy.

Acta Pharm Sin B. 2025 Jan;15(1):484-493. doi: 10.1016/j.apsb.2024.08.008. Epub 2024 Aug 13.

Comparison of 1-Year Clinical Outcomes Between Ticagrelor Versus Clopidogrel in Type 2 Diabetes Patients After Implantation of Small Diameter Stents.

Anatol J Cardiol. 2025 Jan 7;29(2):95-103. doi: 10.14744/AnatolJCardiol.2024.4603.

Clopidogrel-Mediated P2Y Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD.

JACC Basic Transl Sci. 2024 Mar 25;9(7):865-876. doi: 10.1016/j.jacbts.2024.03.003. eCollection 2024 Jul.

Acute Hyperglycemia-Induced Injury in Myocardial Infarction.

Int J Mol Sci. 2024 Aug 4;25(15):8504. doi: 10.3390/ijms25158504.

Tailoring Antithrombotic Regimens for Percutaneous Coronary Intervention Patients with High Bleeding and Ischemic Risk (): Individualized Management and Genotype-Guided De-escalation.

Rev Cardiovasc Med. 2023 Dec 12;24(12):348. doi: 10.31083/j.rcm2412348. eCollection 2023 Dec.

Depression Following Acute Coronary Syndrome: A Review.

Rev Cardiovasc Med. 2023 Sep 5;24(9):247. doi: 10.31083/j.rcm2409247. eCollection 2023 Sep.

Methionine sulfoxide reductase B2 protects against cardiac complications in diabetes mellitus.

Diabetol Metab Syndr. 2024 Jul 5;16(1):149. doi: 10.1186/s13098-024-01390-0.